Trial Profile
A Phase II Study for Anlotinib In Combination With Pemetrexed in the treatment of Patients With Platinum Resistant or Refractory Ovarian Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2021
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Pemetrexed (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 08 Jun 2021 Results (n=27; as of Jan 2021) presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 21 Sep 2020 Results (n=19) presented at the 45th European Society for Medical Oncology Congress.
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology